Plans for the Precision Cancer Medicine Institute University of Oxford

Size: px

Start display at page:

Download "Plans for the Precision Cancer Medicine Institute University of Oxford"

Zoe Mosley
5 years ago
Views:

1 Plans for the Precision Cancer Medicine Institute University of Oxford STFC & Particle Accelerators and Beams group workshop on particle accelerators for medicine 17 th February 2015 Claire Timlin The Particle Therapy Cancer Research Institute is a member of

2 Precision Cancer Medicine Physically Targeted Robotic Surgery Proton Therapy HIFU Physiologically Targeted Molecular Imaging Molecularly Targeted Deep Genomic Sequencing Biomarker Driven Biologically targeted 2 Courtesy of Gillies McKenna 22/10/2014

3 Oxford Precision Medicine Institute Functional and Molecular Imaging Genomics Targeted Agents 3 Particle Therapy Robotic Surgery Courtesy of Gillies McKenna 22/10/2014

Institute Experimental Cancer Medicine Centre Precision Cancer Medicine Institute

4 The New Paradigm Early Stage Cancer Patient Population Health Science Molecular Stratification Structural Genomics Consortium Big Data Institute Target Discovery Institute Experimental Cancer Medicine Centre Precision Cancer Medicine Institute Oxford Cancer Imaging Centre 4 Courtesy of Gillies McKenna Increased Cures 22/10/2014

5 Proton Beam Therapy at the PCMI Precise diagnosis needs to be followed by targeted treatment PBT can reduce collateral dose for some tumours 2 gantry + 1 fixed beam room PBT unit in PCMI PBT partner: ProNova solutions

6 PCMI Strategy PCMI will Focus on cancers of unmet need brain, oesophagus, pancreas, lung, bladder Position Radiotherapy (and Surgery) central to our plans Increase the flow of science into our translational pipeline

7 Redefining the future of Cancer Treatment Joe Matteo President, ProNova Solutions, LLC Research, Development, and Manufacturing Disclaimer: The ProNova SC360 has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the U.S. and is not available for commercial distribution at this time

8 Who is ProNova? ProNova has a strong History of Innovation Developed and commercialized PET & PET/CT technology One of the largest suppliers of Cyclotrons In the world

9 Why ProNova? To deliver a lower-cost, smaller, lighter, more energy efficient solution for Proton Therapy without sacrificing performance and improving upon existing capabilities, making proton more affordable and more accessible to the cancer community

ProNova Design Principles - Workflow Precision, Productivity, Cost Linac like

patient movement Hypo-Fractionation - High current CW beam >300 na - Advanced

room RT treatment room Recognized Technology Leader - Roadmap focus on moving

10 ProNova Design Principles - Workflow Precision, Productivity, Cost Linac like environment treatment angle, open treatment room - 3D imagining, ex-room, no patient movement Hypo-Fractionation - High current CW beam >300 na - Advanced imaging, continuous tracking - Fast scanning IMPT, Range verification RT treatment room RT treatment room Recognized Technology Leader - Roadmap focus on moving tumors, re-planning, workflow, cost - Collaborative research and development ProNova PT treatment room

11 SC360 Treatment Room Open square room provides improved patient access Projection screens provide easy review of therapy information Open room provides clear access for lasers, projectors, Optical imaging, & intercom 11

SC360 Efficient 1, 2, 3+ Room Solution High Current Continuous beam Cyclotron Permanent Magnet Constant Energy Beamline Dual Energy Selection Systems < 1 sec Room Switching 360 Superconducting Gantry

12 SC360 Efficient 1, 2, 3+ Room Solution High Current Continuous beam Cyclotron Permanent Magnet Constant Energy Beamline Dual Energy Selection Systems < 1 sec Room Switching 360 Superconducting Gantry PBS with Variable Spot Size App s & Comp s 0.5 sec Layer Change Dual Energy CBCT Integrated with Positioner 5 RPM, Spiral Capable Auxiliary Positioner Calibration PET at Isocenter Disclaimer: The ProNova SC360 has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the U.S. and is not available for commercial distribution at this time 12

13 SC 360 COMPACT GANTRY

14 Proprietary Superconducting Technology Patented SC gantry for PT Production design exceeds requirements Achromatic bends PBS energy changes Dramatically smaller size, weight, power >2X higher field, <0.5X radius Cryogen free cooling

15 CYCLOTRON VAULT

16 Accelerator Design Inputs Reduced: - Size of device and vault - Cost of device and vault - Operations and maintenance staff fully automated - Power consumption Support Intensity Modulated Proton Therapy (IMPT) - hypofractionated treatments with high dose rate - Fast layer painting requiring continuous scanning - Volumetric repainting Scaleable Design - High volume production 50 cyclotrons per year by Simplified installation, startup, and maintenance

17 ProNova Solutions at Pellissippi Place 55,000 sq ft R&D and Manufacturing facility LEED certified energy efficient facility Opened January 2015 Phase I capacity of 10 two-room systems per year Phase III capacity of 50 two-room systems per year 17

18 Production Layout Phase 3 Capacity (50) two room gantry systems per year (50) super-conducting cyclotrons per year 18

19 The Future of Proton Therapy Oxford / ProNova Collaboration Molecular Targeting Moving Tumors Density Changes Tissue Sparing In-Room Re-planning

Workshop on Hadron Beam Therapy of Cancer Erice, Sicily April 24-May

IONTRIS Synchrotron based PT Solutions from Siemens AG Workshop on Hadron Beam Therapy of Cancer Erice, Sicily April 24-May 1 2009 Matthias Herforth VP Business Development and Communications Siemens AG